Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Scientific Reports|February 7, 2018
The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodentsGuy Griebel, Jeanne Stemmelin, Mati Lopez-Grancha, et al.Pharmacology, Biochemistry, and Behavior|December 1, 2010
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognitionNancy Rogacki, Matilde Lopez-Grancha, Vanessa Naimoli, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 29, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophreniaPhilippe Pichat, Olivier E Bergis, Jean-Paul Terranova, et al.The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing propertiesPaul C Moser, Olivier E Bergis, Samir Jegham, et al.Scientific Reports|October 14, 2016
The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophreniaGuy Griebel, Philippe Pichat, Denis Boulay, et al.Scientific Reports|January 7, 2015
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodentsGuy Griebel, Philippe Pichat, Sandra Beeské, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 5, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profileBruno Biton, Olivier E Bergis, Frédéric Galli, et al.Pageof 1